Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Martinez, Paola ^a   Sundling, Christopher ^a,d   O'Dell, Sijy ^b   Mascola, John R ^b   Wyatt, Richard T ^c   Karlsson Hedestam, Gunilla B ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CPG ODN 2395; CYTOKINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; OLIGODEOXYRIBONUCLEOTIDE; SAPONIN; TOLL LIKE RECEPTOR 9; VIRUS ENVELOPE PROTEIN;

AGONISTS; ANIMAL; ANTIBODY SPECIFICITY; B LYMPHOCYTE; DISEASE MODEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; MUCOSAL IMMUNITY; PLASMA CELL; PRIMATE; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE SUBPOPULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; B-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; MACACA MULATTA; OLIGODEOXYRIBONUCLEOTIDES; PLASMA CELLS; PRIMATES; SAPONINS; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTE SUBSETS; TOLL-LIKE RECEPTOR 9;

EID: 84924873110     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08925     Document Type: Article

References (59)

1. Boyle, J. et al. The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses. Vaccine 25, 2541-2544 (2007).
2. Harper, D. M. et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364, 1757-1765 (2004).
3. Leroux-Roels, I. et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370, 580-589 (2007).
4. Cooper, C. L. et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24, 693-701 (2004).
5. Siegrist, C. A. et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 23, 615-622 (2004).
6. Cooper, C. L. et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22, 3136-3143 (2004).
7. Traore, B. et al. The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali. Vaccine 27, 7299-7303 (2009).
8. Vollmer, J. et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. European journal of immunology 34, 251-262 (2004).
9. Honda, K. et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434, 1035-1040 (2005).
10. Moody, M. A. et al. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. Journal of virology 88, 3329-3339 (2014).
11. Park, H. et al . Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates. J Immunol 190, 4103-4115 (2013).
12. Wiley, S. R. et al. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med 3, 93ra69 (2011).
13. Wille-Reece, U.,Wu, C. Y., Flynn, B. J., Kedl, R. M. & Seder, R. A. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD81 T cell responses. J Immunol 174, 7676-7683 (2005).
14. Kwissa, M., Nakaya, H. I., Oluoch, H. & Pulendran, B. Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 119, 2044-2055 (2012).
15. Gibbs, R. A. et al. Evolutionary and biomedical insights from the rhesus macaque genome. Science 316, 222-234 (2007).
16. Gujer, C., Sundling, C., Seder, R. A., Karlsson Hedestam, G. B. & Lore, K. Human and rhesus plasmacytoid dendritic cell and B-cell responses to Toll-like receptor stimulation. Immunology 134, 257-269 (2011).
17. Sundling, C. et al. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. The Journal of experimental medicine 207, 2003-2017 (2010).
18. Sundling, C. et al. High-Resolution Definition of Vaccine-Elicited B Cell Responses Against the HIV Primary Receptor Binding Site. Sci Transl Med 4, 142ra196 (2012).
19. Mooij, P. et al. Differential CD41 versus CD81 T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. Journal of virology 82, 2975-2988 (2008).
20. Mothe, B. R. et al. Peptide-binding motifs associated with MHC molecules common in Chinese rhesus macaques are analogous to those of human HLA supertypes and include HLA-B27-like alleles. Immunogenetics 65, 371-386 (2013).
21. Sundling, C. et al. Immunization of macaques with soluble HIV type 1 and influenza virus envelope glycoproteins results in a similarly rapid contraction of peripheral B-cell responses after boosting. The Journal of infectious diseases 207, 426-431 (2013).
22. McCluskie, M. J. et al. CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-gamma responses. BioMed research international 2013, 636847 (2013).
23. Siegrist, C.-A. et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 23, 615-622 (2004).
24. Koch, M., Frazier, J., Sodroski, J. & Wyatt, R. Characterization of antibody responses to purified HIV-1 gp120 glycoproteins fused with the molecular adjuvant C3d. Virology 340, 277-284 (2005).
25. Nkolola, J. P. et al. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J Virol 84, 3270-3279 (2010).
26. Mullen, G. E. et al. Enhancement of functional antibody responses to AMA1-C1/ Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 24, 2497-2505 (2006).
27. Decker, J. M. et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. The Journal of experimental medicine 201, 1407-1419 (2005).
28. Forsell, M. N. et al. B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4. PLoS pathogens 4, e1000171 (2008).
29. Sundling, C. et al . Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus. J Virol 84, 9086-9095 (2010).
30. Barnett, S. W. et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. Aids 22, 339-348 (2008).
31. Alpert,M.D. et al.ADCC develops over time during persistent infection with liveattenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 8, e1002890 (2012).
32. Dasari, V. et al. Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus. The Journal of general virology 92, 1021-1031 (2011).
33. Wagner, H. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Current opinion in microbiology 5, 62-69 (2002).
34. Chung, N.,Matthews, K., Klasse, P., Sanders, R. &Moore, J. HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells. Journal of immunology (Baltimore, Md.: 1950) 189, 5257-5265 (2012).
35. Moody, M. A. et al. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. Journal of virology 88, 3329-3339 (2014).
36. Pedersen, G. K. et al.Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(1) T cell responses in man. Human vaccines &immunotherapeutics 10, 2408-2416 (2014).
37. Lovgren Bengtsson, K., Morein, B. & Osterhaus, A. D. ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines 10, 401-403 (2011).
38. Morelli, A. B. et al. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. Journal of medical microbiology 61, 935-943 (2012).
39. Wilson, N. S. et al. Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant. Journal of immunology (Baltimore, Md.: 1950) 192, 3259-3268 (2014).
40. Wilson, N. S. et al. ISCOMATRIX vaccines mediate CD81 T-cell cross-priming by a MyD88-dependent signaling pathway. Immunology and cell biology 90, 540-552 (2012).
41. Jarrossay, D., Napolitani, G., Colonna, M., Sallusto, F. & Lanzavecchia, A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. European journal of immunology 31, 3388-3393 (2001).
42. Kadowaki, N. et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194, 863-869 (2001).
43. Hornung, V. et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168, 4531-4537 (2002).
44. Julien, J. P. et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 1477-1483 (2013).
45. Lyumkis, D. et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342, 1484-1490 (2013).
46. Tran, K. et al . Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc Natl Acad Sci U S A 111, E738-747 (2014).
47. Nkolola, J. P. et al . Comparison of multiple adjuvants on the stability and immunogenicity of a clade CHIV-1 gp140 trimer. Vaccine 32, 2109-2116 (2014).
48. Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. The New England journal of medicine 357, 1903-1915 (2007).
49. Chevrier, S. et al. The BTB-ZF transcription factor Zbtb20 is driven by Irf4 to promote plasma cell differentiation and longevity. The Journal of experimental medicine 211, 827-840 (2014).
50. Wang, Y. & Bhattacharya, D. Adjuvant-specific regulation of long-term antibody responses by ZBTB20. The Journal of experimental medicine 211, 841-856 (2014).
51. Verthelyi, D. et al. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 168, 1659-1663 (2002).
52. Spangberg, M.,Martinez, P., Fredlund, H., Karlsson Hedestam, G. B. & Sundling, C. A simple and safe technique for longitudinal bone marrow aspiration in cynomolgus and rhesus macaques. J Immunol Methods 408, 137-141 (2014).
53. Morner,A. et al.Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J Virol 83, 540-551 (2009).
54. Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79, 10108-10125 (2005).
55. Shu, Y. et al. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 25, 1398-1408 (2007).
56. Mascola, J. R. et al. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J Virol 76, 4810-4821 (2002).
57. Kraft, Z. et al. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J Virol 81, 6402-6411 (2007).
58. Buckner, C. et al. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 320, 167-180 (2004).
59. Leutenegger, C. M. et al. Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA. AIDS Res Hum Retroviruses 17, 243-251 (2001).